UY34656A - Polimorfos de (s)?2?(1?(9h?purin?6?ilamino)propil)?5?fluor?3?fenilquinazolin?4(3h)?ona, composición y método de preparación - Google Patents
Polimorfos de (s)?2?(1?(9h?purin?6?ilamino)propil)?5?fluor?3?fenilquinazolin?4(3h)?ona, composición y método de preparaciónInfo
- Publication number
- UY34656A UY34656A UY0001034656A UY34656A UY34656A UY 34656 A UY34656 A UY 34656A UY 0001034656 A UY0001034656 A UY 0001034656A UY 34656 A UY34656 A UY 34656A UY 34656 A UY34656 A UY 34656A
- Authority
- UY
- Uruguay
- Prior art keywords
- propil
- phenylquinazolin
- ilamino
- purin
- ona
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Polimorfo de (S)?2?(1?(9H?purin?6?ilamino)propil)?5?fluor?3?fenilquinazolin?4(3H)?ona, donde el polimorfo es la Forma I que tiene un patrón de difracción de polvo de rayos X que comprende picos característicos a aproximadamente 17,7 grados 28 y aproximadamente 24,9 grados 28; sus composiciones, métodos para su preparación y para su uso.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261606870P | 2012-03-05 | 2012-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY34656A true UY34656A (es) | 2013-10-31 |
Family
ID=49117265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001034656A UY34656A (es) | 2012-03-05 | 2013-03-05 | Polimorfos de (s)?2?(1?(9h?purin?6?ilamino)propil)?5?fluor?3?fenilquinazolin?4(3h)?ona, composición y método de preparación |
Country Status (32)
Country | Link |
---|---|
US (3) | US8865730B2 (es) |
EP (1) | EP2834241B1 (es) |
JP (2) | JP2015509537A (es) |
KR (1) | KR20140133590A (es) |
CN (2) | CN104334560A (es) |
AP (1) | AP2014007875A0 (es) |
AR (1) | AR090253A1 (es) |
AU (1) | AU2013203620B2 (es) |
BR (1) | BR112014021935A2 (es) |
CA (1) | CA2864305C (es) |
CL (1) | CL2014002358A1 (es) |
CO (1) | CO7071131A2 (es) |
CR (1) | CR20140460A (es) |
EA (3) | EA201690461A1 (es) |
EC (1) | ECSP14020478A (es) |
ES (1) | ES2848273T3 (es) |
HK (1) | HK1206345A1 (es) |
IN (1) | IN2014DN07105A (es) |
MA (1) | MA37379A1 (es) |
MD (1) | MD20140100A2 (es) |
MX (1) | MX2014010656A (es) |
NZ (1) | NZ629684A (es) |
PE (1) | PE20141792A1 (es) |
PH (1) | PH12014501920A1 (es) |
PL (1) | PL2834241T3 (es) |
PT (1) | PT2834241T (es) |
SG (1) | SG11201405446PA (es) |
SI (1) | SI2834241T1 (es) |
TW (1) | TW201350486A (es) |
UY (1) | UY34656A (es) |
WO (1) | WO2013134288A1 (es) |
ZA (1) | ZA201405870B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
US7932260B2 (en) | 2004-05-13 | 2011-04-26 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
AR090253A1 (es) | 2012-03-05 | 2014-10-29 | Gilead Calistoga Llc | Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona |
CN111904962A (zh) | 2012-11-08 | 2020-11-10 | 理森制药股份公司 | 含有PDE4抑制剂和PI3 δ或双重PI3 δ-γ激酶抑制剂的药物组合物 |
WO2015014315A1 (zh) * | 2013-08-01 | 2015-02-05 | 杭州普晒医药科技有限公司 | 一种抑制剂的晶型及其制备方法和用途 |
US20160244452A1 (en) * | 2013-10-21 | 2016-08-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
IN2013MU03641A (es) | 2013-11-20 | 2015-07-31 | Cadila Healthcare Ltd | |
MX2016008259A (es) | 2013-12-20 | 2016-10-13 | Gilead Calistoga Llc | Metodo de proceso para inhibidores de fosfatidilinositol 3-cinasa. |
US9708327B2 (en) | 2013-12-20 | 2017-07-18 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
EP2979692A1 (en) | 2014-07-30 | 2016-02-03 | Sandoz Ag | Dosage form comprising a pressure sensitive solid form of an active pharmaceutical ingredient |
EP3031808B1 (en) | 2014-12-09 | 2018-06-27 | ratiopharm GmbH | Salt of idelalisib |
WO2016097314A1 (en) * | 2014-12-19 | 2016-06-23 | Sandoz Ag | Amorphous and crystalline forms of idelalisib and process for forming the same |
EP3048104A1 (en) | 2015-01-20 | 2016-07-27 | Sandoz AG | Amorphous and crystalline forms of idelalisib and process for forming the same |
US20180064714A1 (en) * | 2015-03-13 | 2018-03-08 | Mylan Laboratories Ltd | Process for the Preparation of Amorphous Idelalisib and its Premix |
CN106146500A (zh) * | 2015-03-26 | 2016-11-23 | 江苏豪森药业集团有限公司 | 5-氟-3-苯基-2-[(1s)-1-(9h-嘌呤-6-基氨基)丙基]-4(3h)-喹唑啉酮晶型及其制备方法 |
CN106146501A (zh) * | 2015-03-26 | 2016-11-23 | 江苏豪森药业集团有限公司 | 一种无定型激酶抑制剂的制备方法 |
WO2016157136A1 (en) | 2015-04-02 | 2016-10-06 | Mylan Laboratories Ltd | Crystalline forms of idelalisib |
CN104892612B (zh) * | 2015-04-15 | 2017-12-19 | 上海方楠生物科技有限公司 | 一种艾德力布的无定型物及其制备方法 |
CN106146503A (zh) * | 2015-04-16 | 2016-11-23 | 上海医药工业研究院 | 一种Idelalisib的制备方法 |
CZ2015347A3 (cs) | 2015-05-22 | 2016-11-30 | Zentiva, K.S. | Pevné formy 5-fluor-3-fenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]chinazolin-4-onu a jejich příprava |
CN106279171A (zh) * | 2015-06-09 | 2017-01-04 | 南京安源生物医药科技有限公司 | 一种Idelalisib的制备方法 |
AR105238A1 (es) | 2015-07-02 | 2017-09-20 | Hoffmann La Roche | Compuestos de benzoxacepina oxazolidinona y métodos de uso |
CN107995911B (zh) | 2015-07-02 | 2020-08-04 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 |
WO2017009333A1 (en) * | 2015-07-13 | 2017-01-19 | Synthon B.V. | Method for purifying idelalisib |
KR20240052084A (ko) | 2015-08-21 | 2024-04-22 | 모르포시스 아게 | 조합 및 이의 용도 |
CZ2015575A3 (cs) * | 2015-08-26 | 2017-03-08 | Zentiva, K.S. | Soli 5-fluoro-3-fenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]quinazolin-4-onu a jejich příprava |
CN106565716B (zh) * | 2015-10-10 | 2021-06-15 | 上海创诺制药有限公司 | 一种Idelalisib晶型A及其制备方法 |
HU231016B1 (hu) * | 2015-11-30 | 2019-11-28 | Egis Gyógyszergyár Zrt. | Idelalisib új polimorf és szolvát formája |
WO2017175184A1 (en) * | 2016-04-07 | 2017-10-12 | Laurus Labs Limited | Process for preparation of amorphous form of idelalisib |
EP3272348A1 (en) | 2016-07-21 | 2018-01-24 | LEK Pharmaceuticals d.d. | Pharmaceutical composition comprising idelalisib |
CN106632337B (zh) * | 2016-10-18 | 2018-11-20 | 湖北生物医药产业技术研究院有限公司 | 艾代拉里斯的晶型、药物组合物、制备方法和用途 |
WO2018198131A1 (en) | 2017-04-24 | 2018-11-01 | Natco Pharma Limited | Process for the preparation of amorphous idelalisib |
CN107573345B (zh) * | 2017-09-12 | 2020-01-10 | 浙江乐普药业股份有限公司 | 一种艾代拉利司及其中间体的制备方法 |
CN109575027A (zh) * | 2017-09-29 | 2019-04-05 | 宁波爱诺医药科技有限公司 | 一种抗肿瘤药物艾德力布的一水合物及其制备方法 |
WO2019178596A1 (en) | 2018-03-16 | 2019-09-19 | Johnson Matthey Public Limited Company | Pyridine or n,n-dimethyl acetamide solvated solid state forms of solvated idelalisib, their use and preparation |
EP3903828A4 (en) | 2018-12-21 | 2022-10-05 | Daiichi Sankyo Company, Limited | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR |
GB202109006D0 (en) * | 2021-06-23 | 2021-08-04 | Anglo American Minerio De Ferro Brasil S/A | Method of and system for operating a grinding mill |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1249281B (es) | 1963-05-18 | |||
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
DE2027645A1 (de) | 1970-06-05 | 1971-12-09 | Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz | Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel |
US3897432A (en) | 1971-04-21 | 1975-07-29 | Merck & Co Inc | Substituted benzimidazole derivatives |
NL7204972A (es) | 1971-04-21 | 1972-10-24 | ||
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
DE2644265C2 (de) | 1976-09-30 | 1983-02-10 | Bayer Ag, 5090 Leverkusen | Chinazoline |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4183931A (en) | 1977-09-08 | 1980-01-15 | Research Corporation | 2-Ketoalkyl-4(3H)-quinazolinones |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
DE2812635A1 (de) | 1978-03-22 | 1979-09-27 | Bayer Ag | Heterocyclische verbindungen |
JPS55118917A (en) | 1979-03-06 | 1980-09-12 | Mitsubishi Electric Corp | Production of quinazolone ring-containing epoxy resin |
JPS55118918A (en) | 1979-03-06 | 1980-09-12 | Mitsubishi Electric Corp | Production of quinazolone ring-containing epoxy resin |
US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
JPS6017375B2 (ja) | 1979-06-20 | 1985-05-02 | 三菱電機株式会社 | ポリアミド樹脂の製造方法 |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
USRE35862E (en) | 1986-08-18 | 1998-07-28 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
NL8720442A (nl) | 1986-08-18 | 1989-04-03 | Clinical Technologies Ass | Afgeefsystemen voor farmacologische agentia. |
US6696250B1 (en) | 1986-12-03 | 2004-02-24 | Competitive Technologies, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
US5225347A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
FR2675803B1 (fr) | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
EP0525960B1 (en) | 1991-06-18 | 1996-03-20 | American Home Products Corporation | Use of rapamycin for the treatment of adult T-cell leukemia/lymphoma |
CA2118130A1 (en) | 1992-04-14 | 1993-10-28 | Jean M. J. Frechet | Dendritic based macromolecules and method of production |
US5658780A (en) | 1992-12-07 | 1997-08-19 | Ribozyme Pharmaceuticals, Inc. | Rel a targeted ribozymes |
GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
US5378725A (en) | 1993-07-19 | 1995-01-03 | The Arizona Board Of Regents | Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof |
GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
FI951367A (fi) | 1994-03-28 | 1995-09-29 | Japan Energy Corp | Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit) |
US5480906A (en) | 1994-07-01 | 1996-01-02 | Eli Lilly And Company | Stereochemical Wortmannin derivatives |
WO1996004923A1 (en) | 1994-08-12 | 1996-02-22 | Pro-Neuron, Inc. | Methods for treating sepsis or inflammatory diseases with oxypurine nucleosides |
US5561138A (en) | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
US6043062A (en) | 1995-02-17 | 2000-03-28 | The Regents Of The University Of California | Constitutively active phosphatidylinositol 3-kinase and uses thereof |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5948664A (en) | 1996-02-29 | 1999-09-07 | The Regents Of The University Of California | PI 3-kinase polypeptides |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
ES2198546T3 (es) | 1996-05-15 | 2004-02-01 | Pfizer Inc. | 4(3h)-quinazolinonas 2,3,6 trisustituidas. |
GB9611460D0 (en) | 1996-06-01 | 1996-08-07 | Ludwig Inst Cancer Res | Novel lipid kinase |
US5858753A (en) | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
TW528755B (en) | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
IL142649A (en) | 1996-12-31 | 2004-12-15 | Reddy Research Foundation | Azole derivatives |
GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
IL130900A0 (en) | 1997-02-28 | 2001-01-28 | Pfizer Prod Inc | Atropisomers of 3-aryl-4(3H)- quinazolinones and their use as ampa-receptor antagonsts |
DE69831446T2 (de) | 1997-06-09 | 2006-06-14 | Pfizer Prod Inc | Chinazolin-4-on AMPA Antagonisten |
US6277981B1 (en) | 1997-07-03 | 2001-08-21 | Thomas Jefferson University | Method for design and selection of efficacious antisense oligonucleotides |
IL125950A0 (en) | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
AU2108299A (en) | 1998-01-08 | 1999-07-26 | University Of Virginia Patent Foundation | A2A adenosine receptor agonists |
DE69828445D1 (de) | 1998-04-23 | 2005-02-03 | Reddys Lab Ltd Dr | Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen |
US6048970A (en) | 1998-05-22 | 2000-04-11 | Incyte Pharmaceuticals, Inc. | Prostate growth-associated membrane proteins |
US6100090A (en) | 1999-06-25 | 2000-08-08 | Isis Pharmaceuticals Inc. | Antisense inhibition of PI3K p85 expression |
US6046049A (en) | 1999-07-19 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of PI3 kinase p110 delta expression |
CA2388646C (en) | 1999-10-27 | 2009-01-27 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
CZ20022332A3 (cs) | 2000-01-07 | 2003-01-15 | Transform Pharmaceuticals, Inc. | Sestava vzorků |
JP4820518B2 (ja) | 2000-01-24 | 2011-11-24 | アストラゼネカ アクチボラグ | モルホリノ置換化合物治療薬 |
DE60106409T2 (de) | 2000-02-07 | 2006-02-02 | Bristol-Myers Squibb Co. | 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen |
ATE502941T1 (de) | 2000-04-25 | 2011-04-15 | Icos Corp | Hemmer der menschlichen phosphatidyl-inositol-3- kinase delta |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
WO2003106622A2 (en) | 2002-05-30 | 2003-12-24 | The Children's Hospital Of Philadelphia | Methods for treatment of acute lymphocytic leukemia |
BR0312650A (pt) | 2002-07-10 | 2005-05-03 | Applied Research Systems | Derivados de benzeno fundido azolidinona-vinila |
US20040092561A1 (en) | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
GB0217777D0 (en) | 2002-07-31 | 2002-09-11 | Novartis Ag | Organic compounds |
US20040023390A1 (en) | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
CA2400254A1 (en) | 2002-09-19 | 2004-03-19 | University Health Network | Compositions and methods for treating heart disease |
MXPA05001808A (es) | 2002-09-30 | 2005-08-16 | Bayer Pharmaceuticals Corp | Derivados de azol-pirimidina condensados. |
BR0316386A (pt) | 2002-12-06 | 2005-09-27 | Warner Lambert Co | Benzoxazin-3-onas e seus derivados como inibidores de p13k |
CA2510851A1 (en) | 2002-12-20 | 2004-07-08 | Warner-Lambert Company Llc | Benzoxazines and derivatives thereof as inhibitors of pi3ks |
BRPI0409063A (pt) | 2003-04-03 | 2006-03-28 | Semafore Pharmaceuticals Inc | pró medicamentos de inibidor de pi-3 cinase |
EP1636211A1 (en) | 2003-06-05 | 2006-03-22 | Warner-Lambert Company | 3-arylsulfanyl and 3-heteroarylsulfanyl substituted benzo[b]thiophenes as therapeutic agents |
CA2527573A1 (en) | 2003-06-05 | 2004-12-16 | Warner-Lambert Company Llc | Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents |
WO2004108709A1 (en) | 2003-06-05 | 2004-12-16 | Warner-Lambert Company Llc | Tetrazol benzofurancarboxamides with p13k aktivity as therapeutic agents |
US20040259926A1 (en) | 2003-06-05 | 2004-12-23 | Bruendl Michelle M. | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents |
WO2004108714A1 (en) | 2003-06-05 | 2004-12-16 | Warner-Lambert Company Llc | Cycloalkylsulfanyl substituted benzo[b]thiophenes as therapeutic agents |
JP2006526605A (ja) | 2003-06-05 | 2006-11-24 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | 治療剤としての3−置換インドール類及びそれらの誘導体 |
US20050054614A1 (en) | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
WO2005016348A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
WO2005067901A2 (en) | 2004-01-08 | 2005-07-28 | Michigan State University | Methods for treating and preventing hypertension and hypertension-related disorders |
US7932260B2 (en) | 2004-05-13 | 2011-04-26 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
WO2005112935A1 (en) | 2004-05-13 | 2005-12-01 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
EP1755609A1 (en) | 2004-05-25 | 2007-02-28 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells |
WO2005120511A1 (en) | 2004-06-04 | 2005-12-22 | Icos Corporation | Methods for treating mast cell disorders |
EP1885356A2 (en) | 2005-02-17 | 2008-02-13 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
WO2009058361A1 (en) | 2007-10-31 | 2009-05-07 | Dynavax Technologies Corp. | Inhibition of type i ifn production |
ES2674719T3 (es) * | 2008-11-13 | 2018-07-03 | Gilead Calistoga Llc | Terapias para neoplasias hematológicas |
CA2745280A1 (en) | 2008-12-04 | 2010-06-10 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders |
US8889695B2 (en) | 2008-12-24 | 2014-11-18 | Prana Biotechnology Limited | Quinazolinone compounds |
EP2411391A1 (en) | 2009-03-24 | 2012-02-01 | Gilead Calistoga LLC | Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
CN102458410A (zh) | 2009-04-20 | 2012-05-16 | 吉联亚·卡利斯托加有限责任公司 | 治疗实体瘤的方法 |
WO2011032277A1 (en) | 2009-09-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | Quinazolinone derivatives as viral polymerase inhibitors |
AU2011265258A1 (en) * | 2010-06-11 | 2013-01-10 | Calistoga Pharmaceuticals, Inc. | Methods of treating hematological disorders with quinazolinone compounds in selected patients |
US20130143902A1 (en) * | 2011-12-02 | 2013-06-06 | Gilead Calistoga Llc | Compositions and methods of treating a proliferative disease with a quinazolinone derivative |
AR090253A1 (es) | 2012-03-05 | 2014-10-29 | Gilead Calistoga Llc | Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona |
US9708327B2 (en) | 2013-12-20 | 2017-07-18 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
-
2013
- 2013-03-05 AR ARP130100721A patent/AR090253A1/es unknown
- 2013-03-05 US US13/786,222 patent/US8865730B2/en active Active
- 2013-03-05 PL PL13757230T patent/PL2834241T3/pl unknown
- 2013-03-05 TW TW102107672A patent/TW201350486A/zh unknown
- 2013-03-05 MX MX2014010656A patent/MX2014010656A/es unknown
- 2013-03-05 JP JP2014561048A patent/JP2015509537A/ja not_active Withdrawn
- 2013-03-05 AU AU2013203620A patent/AU2013203620B2/en active Active
- 2013-03-05 CN CN201380011784.1A patent/CN104334560A/zh active Pending
- 2013-03-05 KR KR1020147027588A patent/KR20140133590A/ko not_active Application Discontinuation
- 2013-03-05 PE PE2014001310A patent/PE20141792A1/es not_active Application Discontinuation
- 2013-03-05 PT PT137572301T patent/PT2834241T/pt unknown
- 2013-03-05 EA EA201690461A patent/EA201690461A1/ru unknown
- 2013-03-05 IN IN7105DEN2014 patent/IN2014DN07105A/en unknown
- 2013-03-05 SI SI201331843T patent/SI2834241T1/sl unknown
- 2013-03-05 AP AP2014007875A patent/AP2014007875A0/xx unknown
- 2013-03-05 CA CA2864305A patent/CA2864305C/en active Active
- 2013-03-05 BR BR112014021935A patent/BR112014021935A2/pt not_active IP Right Cessation
- 2013-03-05 EP EP13757230.1A patent/EP2834241B1/en active Active
- 2013-03-05 NZ NZ629684A patent/NZ629684A/en unknown
- 2013-03-05 EA EA201691327A patent/EA201691327A1/ru unknown
- 2013-03-05 ES ES13757230T patent/ES2848273T3/es active Active
- 2013-03-05 WO PCT/US2013/029157 patent/WO2013134288A1/en active Application Filing
- 2013-03-05 CN CN201610547374.4A patent/CN106146506A/zh active Pending
- 2013-03-05 MD MDA20140100A patent/MD20140100A2/ro not_active Application Discontinuation
- 2013-03-05 SG SG11201405446PA patent/SG11201405446PA/en unknown
- 2013-03-05 EA EA201491473A patent/EA025407B1/ru unknown
- 2013-03-05 UY UY0001034656A patent/UY34656A/es not_active Application Discontinuation
-
2014
- 2014-08-11 ZA ZA2014/05870A patent/ZA201405870B/en unknown
- 2014-08-26 PH PH12014501920A patent/PH12014501920A1/en unknown
- 2014-09-05 CL CL2014002358A patent/CL2014002358A1/es unknown
- 2014-09-12 CO CO14202424A patent/CO7071131A2/es unknown
- 2014-09-22 US US14/493,261 patent/US9469643B2/en active Active
- 2014-09-26 MA MA37379A patent/MA37379A1/fr unknown
- 2014-09-26 EC ECIEPI201420478A patent/ECSP14020478A/es unknown
- 2014-10-01 CR CR20140460A patent/CR20140460A/es unknown
-
2015
- 2015-07-21 HK HK15106935.8A patent/HK1206345A1/xx unknown
-
2016
- 2016-03-04 JP JP2016042418A patent/JP2016104823A/ja active Pending
- 2016-09-06 US US15/257,053 patent/US10730879B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY34656A (es) | Polimorfos de (s)?2?(1?(9h?purin?6?ilamino)propil)?5?fluor?3?fenilquinazolin?4(3h)?ona, composición y método de preparación | |
PH12016501763A1 (en) | Multispecific antibodies | |
UY34824A (es) | Nucleósidos de espirooxetano de uracilo | |
UY34566A (es) | 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
UY34765A (es) | Compuestos novedosos. | |
MX2015013163A (es) | Complejos multiespecificos multivalente y monovalentes y sus usos. | |
UY34697A (es) | Métodos para preparar análogos de nucleótidos | |
UY34591A (es) | Compuestos de imidazopirrolidinona | |
AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
UY34585A (es) | Compuestos b-lactámicos sustituidos con amidina, su preparación y uso | |
UY34749A (es) | Proceso para producir biocombustible y componentes de biocombustible. | |
UY34763A (es) | Inhibidores de la agregación plaquetaria | |
UY34342A (es) | ?derivados de pirrolopirimidina y purina?. | |
UY34559A (es) | Inhibidores de bromodominios | |
UY34817A (es) | Tienopirimidinas | |
UY34767A (es) | Inhibidores cíclicos del enlace éter de dgat1 | |
EA201792612A1 (ru) | 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot | |
UY34863A (es) | Antagonistas de iap | |
TR201905787T4 (tr) | Liyofilize TAT-NR2B9C formülasyonu. | |
CL2018000756A1 (es) | Métodos moleculares de aseguramiento de la calidad para su uso en la secuenciación | |
UY34629A (es) | Inhibidores de pirazolopirimidinilo de enzima activadora de ubicuitina | |
EA201590503A1 (ru) | Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями | |
UY34791A (es) | N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2- dihidroquinolina-3-carboxamida | |
EA201591709A1 (ru) | 5-бром-индирубины | |
UY34677A (es) | Imidazopiridazinas sustituidas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20210526 |